{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:39:41Z","timestamp":1791261581463,"version":"4.1.0"},"reference-count":222,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81873444, No. 82070213, and No.82370196"],"award-info":[{"award-number":["No. 81873444, No. 82070213, and No.82370196"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06742-6","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:10:06Z","timestamp":1768461006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Next-generation CAR-T therapy for acute myeloid leukemia: bridging innovation with clinical translation"],"prefix":"10.1007","volume":"105","author":[{"given":"Xumeng","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Ming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"6742_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1260470","volume":"14","author":"L P\u00e9rez-Amill","year":"2023","unstructured":"P\u00e9rez-Amill L, Bataller \u00c0, Delgado J, Esteve J, Juan M, Klein-Gonz\u00e1lez N (2023) Advancing CART therapy for acute myeloid leukemia: recent breakthroughs and strategies for future development. Front Immunol 14:1260470","journal-title":"Front Immunol"},{"issue":"22","key":"6742_CR2","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.3390\/cancers13225722","volume":"13","author":"M Fleischmann","year":"2021","unstructured":"Fleischmann M, Schnetzke U, Hochhaus A, Scholl S (2021) Management of acute myeloid leukemia: current treatment options and future perspectives. Cancers 13(22):5722","journal-title":"Cancers"},{"key":"6742_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.blre.2019.02.001","volume":"35","author":"JB Lee","year":"2019","unstructured":"Lee JB, Chen B, Vasic D, Law AD, Zhang L (2019) Cellular immunotherapy for acute myeloid leukemia: how specific should it be? Blood Rev 35:18\u201331","journal-title":"Blood Rev"},{"key":"6742_CR4","doi-asserted-by":"crossref","unstructured":"Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ et al (2009) Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. Jama 301(22):2349\u20132361","DOI":"10.1001\/jama.2009.813"},{"key":"6742_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN (2019) Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev 34:45\u201355","journal-title":"Blood Rev"},{"key":"6742_CR6","doi-asserted-by":"crossref","unstructured":"Bartoszewska E, Tota M, Kisielewska M, Skowron I, Sebastianka K, Stefaniak O et al (2024) Overcoming Antigen Escape and T-Cell Exhaustion in CAR-T Therapy for Leukemia. Cells 13(18):1596","DOI":"10.3390\/cells13181596"},{"key":"6742_CR7","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3389\/fimmu.2020.01109","volume":"11","author":"A Rodriguez-Garcia","year":"2020","unstructured":"Rodriguez-Garcia A, Palazon A, Noguera-Ortega E, Powell DJ, Guedan S (2020) CAR-T cells hit the tumor microenvironment: strategies to overcome tumor escape. Front Immunol 11:1109","journal-title":"Front Immunol"},{"issue":"3","key":"6742_CR8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3390\/cancers14030497","volume":"14","author":"J Marvin-Peek","year":"2022","unstructured":"Marvin-Peek J, Savani BN, Olalekan OO, Dholaria B (2022) Challenges and advances in chimeric antigen receptor therapy for acute myeloid leukemia. Cancers (Basel) 14(3):497","journal-title":"Cancers (Basel)"},{"key":"6742_CR9","doi-asserted-by":"crossref","unstructured":"Michelozzi IM, Kirtsios E, Giustacchini A (2021) Driving CAR T stem cell targeting in acute myeloid leukemia: the roads to success. Cancers 13(11):2816","DOI":"10.3390\/cancers13112816"},{"issue":"1","key":"6742_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000845","volume":"8","author":"ML Baroni","year":"2020","unstructured":"Baroni ML, Sanchez Martinez D, Gutierrez Aguera F, Roca Ho H, Castella M, Zanetti SR et al (2020) 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo. J Immunother Cancer 8(1):e000845","journal-title":"J Immunother Cancer"},{"issue":"1","key":"6742_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3233\/CBM-201519","volume":"29","author":"S Aref","year":"2020","unstructured":"Aref S, Azmy E, El Ghannam D, Haroun M, Ibrahim L, Sabry M (2020) Clinical value of CD25\/CD123 co-expression in acute myeloid leukemia patients. Cancer Biomark 29(1):9\u201316","journal-title":"Cancer Biomark"},{"issue":"6","key":"6742_CR12","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1080\/17474086.2021.1935855","volume":"14","author":"MR Espinoza-Gutarra","year":"2021","unstructured":"Espinoza-Gutarra MR, Green SD, Zeidner JF, Konig H (2021) CD123-targeted therapy in acute myeloid leukemia. Expert Rev Hematol 14(6):561\u201376","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"6742_CR13","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3390\/cancers13030496","volume":"13","author":"VM Perriello","year":"2021","unstructured":"Perriello VM, Gionfriddo I, Rossi R, Milano F, Mezzasoma F, Marra A et al (2021) CD123 is consistently expressed on NPM1-mutated AML cells. Cancers 13(3):496","journal-title":"Cancers"},{"issue":"18","key":"6742_CR14","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","volume":"122","author":"A Mardiros","year":"2013","unstructured":"Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE et al (2013) T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood 122(18):3138\u20133148","journal-title":"Blood"},{"issue":"15","key":"6742_CR15","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","volume":"123","author":"S Gill","year":"2014","unstructured":"Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL et al (2014) Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor\u2013modified T cells. Blood 123(15):2343\u20132354","journal-title":"Blood"},{"key":"6742_CR16","doi-asserted-by":"crossref","unstructured":"Wermke M, Kraus S, Ehninger A, Bargou RC, Goebeler ME, Middeke JM et al (2021) Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML. Blood 137(22):3145\u20138","DOI":"10.1182\/blood.2020009759"},{"issue":"4","key":"6742_CR17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/13543784.2018.1452911","volume":"27","author":"RB Walter","year":"2018","unstructured":"Walter RB (2018) Investigational CD33-targeted therapeutics for acute myeloid leukemia. Expert Opin Investig Drugs 27(4):339\u2013348","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"6742_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12885-021-09116-5","volume":"22","author":"J Liu","year":"2022","unstructured":"Liu J, Tong J, Yang H (2022) Targeting CD33 for acute myeloid leukemia therapy. BMC Cancer 22(1):24","journal-title":"BMC Cancer"},{"issue":"8","key":"6742_CR19","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/leu.2015.52","volume":"29","author":"SS Kenderian","year":"2015","unstructured":"Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJD et al (2015) CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia 29(8):1637\u201347","journal-title":"Leukemia"},{"issue":"11","key":"6742_CR20","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","volume":"35","author":"FP Tambaro","year":"2021","unstructured":"Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P et al (2021) Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia. Leukemia 35(11):3282\u20136","journal-title":"Leukemia"},{"issue":"9","key":"6742_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003149","volume":"9","author":"H Qin","year":"2021","unstructured":"Qin H, Yang L, Chukinas JA, Shah N, Tarun S, Pouzolles M et al (2021) Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design. J Immunother Cancer 9(9):e003149","journal-title":"J Immunother Cancer"},{"issue":"9","key":"6742_CR22","doi-asserted-by":"publisher","first-page":"e162593","DOI":"10.1172\/JCI162593","volume":"134","author":"J Appelbaum","year":"2024","unstructured":"Appelbaum J, Price AE, Oda K, Zhang J, Leung WH, Tampella G et al (2024) Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized Rapamycin dosing. J Clin Invest 134(9):e162593","journal-title":"J Clin Invest"},{"issue":"5","key":"6742_CR23","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/bjh.15711","volume":"184","author":"M Bill","year":"2019","unstructured":"Bill M, Aggerholm A, Kjeldsen E, Roug AS, Hokland P, Nederby L (2019) Revisiting CLEC12A as leukaemic stem cell marker in AML: highlighting the necessity of precision diagnostics in patients eligible for targeted therapy. Br J Haematol 184(5):769\u2013781","journal-title":"Br J Haematol"},{"key":"6742_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.blre.2018.10.003","volume":"34","author":"LM Morsink","year":"2019","unstructured":"Morsink LM, Walter RB, Ossenkoppele GJ (2019) Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia. Blood Rev 34:26\u201333","journal-title":"Blood Rev"},{"issue":"1","key":"6742_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","volume":"11","author":"J Wang","year":"2018","unstructured":"Wang J, Chen S, Xiao W, Li W, Wang L, Yang S et al (2018) CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J Hematol Oncol 11(1):7","journal-title":"J Hematol Oncol"},{"issue":"3","key":"6742_CR26","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/ejh.13672","volume":"107","author":"LL Ngai","year":"2021","unstructured":"Ngai LL, Ma CY, Maguire O, Do AD, Robert A, Logan AC et al (2021) Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34\u2009+\u2009blasts of AML patients. Eur J Haematol 107(3):343\u201353","journal-title":"Eur J Haematol"},{"issue":"2","key":"6742_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001229","volume":"8","author":"P Ataca Atilla","year":"2020","unstructured":"Ataca Atilla P, McKenna MK, Tashiro H, Srinivasan M, Mo F, Watanabe N et al (2020) Modulating TNF\u03b1 activity allows transgenic IL15-expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J Immunother Cancer 8(2):e001229","journal-title":"J Immunother Cancer"},{"key":"6742_CR28","doi-asserted-by":"crossref","unstructured":"Jin X, Zhang M, Sun R, Lyu H, Xiao X, Zhang X et al (2022) First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia. J Hematol Oncol 15(1):88","DOI":"10.1186\/s13045-022-01308-1"},{"key":"6742_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1389227","volume":"15","author":"X Miao","year":"2024","unstructured":"Miao X, Shuai Y, Han Y, Zhang N, Liu Y, Yao H et al (2024) Case report: donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed\/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission. Front Immunol 15:1389227","journal-title":"Front Immunol"},{"key":"6742_CR30","doi-asserted-by":"crossref","unstructured":"Zhang H, Wang P, Li Z, He Y, Gan W, Jiang H (2021) Anti-CLL1 chimeric antigen receptor T-cell therapy in children with relapsed\/refractory acute myeloid leukemia. Clin Cancer Res 27(13):3549\u201355","DOI":"10.1158\/1078-0432.CCR-20-4543"},{"issue":"Supplement 1","key":"6742_CR31","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1182\/blood-2023-189901","volume":"142","author":"M Murtadha","year":"2023","unstructured":"Murtadha M, Park M, Zhu Y, Caserta E, Napolitano O, Tandoh T et al (2023) CD38-directed, single-chain T cell-engager targets leukemia stem cells through IFN\u03b3-induced CD38 expression. Blood 142(Supplement 1):2797\u20132797","journal-title":"Blood"},{"issue":"3","key":"6742_CR32","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.3324\/haematol.2018.192757","volume":"104","author":"J Naik","year":"2019","unstructured":"Naik J, Themeli M, de Jong-Korlaar R, Ruiter RWJ, Poddighe PJ, Yuan H et al (2019) CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Haematologica 104(3):e100\u2013e103","journal-title":"Haematologica"},{"issue":"16","key":"6742_CR33","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1182\/blood.2023023786","volume":"143","author":"AJ Lamble","year":"2024","unstructured":"Lamble AJ, Rau RE (2024) IFN-\u03b3 and CD38 in AML: a T-cell engagement made in heaven? Blood 143(16):1556\u20131557","journal-title":"Blood"},{"issue":"12","key":"6742_CR34","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1038\/cti.2016.73","volume":"5","author":"T Yoshida","year":"2016","unstructured":"Yoshida T, Mihara K, Takei Y, Yanagihara K, Kubo T, Bhattacharyya J et al (2016) All-trans retinoic acid enhances cytotoxic effect of T cells with an anti-CD38 chimeric antigen receptor in acute myeloid leukemia. Clin Translational Immunol 5(12):e116","journal-title":"Clin Translational Immunol"},{"issue":"1","key":"6742_CR35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-021-01092-4","volume":"14","author":"Q Cui","year":"2021","unstructured":"Cui Q, Qian C, Xu N, Kang L, Dai H, Cui W et al (2021) CD38-directed CAR-T cell therapy: A novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol 14(1):82","journal-title":"J Hematol Oncol"},{"issue":"2","key":"6742_CR36","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3324\/haematol.2020.271908","volume":"107","author":"M Gurney","year":"2022","unstructured":"Gurney M, Stikvoort A, Nolan E, Kirkham-McCarthy L, Khoruzhenko S, Shivakumar R et al (2022) CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide. Haematologica 107(2):437\u2013445","journal-title":"Haematologica"},{"issue":"20","key":"6742_CR37","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","volume":"122","author":"M Casucci","year":"2013","unstructured":"Casucci M, Nicolis di Robilant B, Falcone L, Camisa B, Norelli M, Genovese P et al (2013) CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 122(20):3461\u20133472","journal-title":"Blood"},{"issue":"1","key":"6742_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0092-8674(91)90403-L","volume":"65","author":"U G\u00fcnthert","year":"1991","unstructured":"G\u00fcnthert U, Hofmann M, Rudy W, Reber S, Z\u00f6ller M, Hau\u03b2mann I et al (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65(1):13\u201324","journal-title":"Cell"},{"issue":"9","key":"6742_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1043","volume":"12","author":"L Tang","year":"2022","unstructured":"Tang L, Huang H, Tang Y, Li Q, Wang J, Li D et al (2022) CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations. Clin Transl Med 12(9):e1043","journal-title":"Clin Transl Med"},{"issue":"2","key":"6742_CR40","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/cas.14274","volume":"111","author":"H Kiyoi","year":"2020","unstructured":"Kiyoi H, Kawashima N, Ishikawa Y (2020) FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development. Cancer Sci 111(2):312\u2013322","journal-title":"Cancer Sci"},{"issue":"5","key":"6742_CR41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","volume":"11","author":"N Daver","year":"2021","unstructured":"Daver N, Venugopal S, Ravandi F (2021) FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer J 11(5):104","journal-title":"Blood Cancer J"},{"key":"6742_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.612880","volume":"10","author":"VE Kennedy","year":"2020","unstructured":"Kennedy VE, Smith CC (2020) FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies. Front Oncol 10:612880","journal-title":"Front Oncol"},{"issue":"8","key":"6742_CR43","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.3390\/cancers15082312","volume":"15","author":"K Fedorov","year":"2023","unstructured":"Fedorov K, Maiti A, Konopleva M (2023) Targeting FLT3 mutation in acute myeloid leukemia: current strategies and future directions. Cancers 15(8):2312","journal-title":"Cancers"},{"issue":"11","key":"6742_CR44","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3390\/vaccines9111238","volume":"9","author":"V Maiorova","year":"2021","unstructured":"Maiorova V, Mollaev MD, Vikhreva P, Kulakovskaya E, Pershin D, Chudakov DM et al (2021) Natural Flt3Lg-Based chimeric antigen receptor (Flt3-CAR) T cells successfully target Flt3 on AML cell lines. Vaccines 9(11):1238","journal-title":"Vaccines"},{"issue":"8","key":"6742_CR45","doi-asserted-by":"publisher","first-page":"7626","DOI":"10.3390\/ijms24087626","volume":"24","author":"V Maiorova","year":"2023","unstructured":"Maiorova V, Mollaev MD, Vikhreva P, Chudakov DM, Kibardin A, Maschan MA et al (2023) Mutated Flt3Lg provides reduced Flt3 recycling compared to wild-type Flt3Lg and retains the specificity of Flt3Lg-based CAR T-cell targeting in AML models. Int J Mol Sci 24(8):7626","journal-title":"Int J Mol Sci"},{"issue":"19","key":"6742_CR46","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1182\/blood.2020009192","volume":"138","author":"H Jetani","year":"2021","unstructured":"Jetani H, Navarro-Bail\u00f3n A, Maucher M, Frenz S, Verbruggen C, Yeguas A et al (2021) Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. Blood 138(19):1830\u20131842","journal-title":"Blood"},{"issue":"19","key":"6742_CR47","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1182\/blood.2021013184","volume":"138","author":"S Ghorashian","year":"2021","unstructured":"Ghorashian S, Pule M (2021) Siglec-6 CAR t: magic bullet for a moving target. Blood 138(19):1786\u20131787","journal-title":"Blood"},{"issue":"9","key":"6742_CR48","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1038\/s41375-021-01188-3","volume":"35","author":"D Kovalovsky","year":"2021","unstructured":"Kovalovsky D, Yoon JH, Cyr MG, Simon S, Voynova E, Rader C et al (2021) Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia. Leukemia 35(9):2581\u201391","journal-title":"Leukemia"},{"key":"6742_CR49","doi-asserted-by":"crossref","unstructured":"Nunes J, Tafesse R, Mao C, Purcell M, Mo X, Zhang L et al (2024) Siglec-6 as a therapeutic target for cell migration and adhesion in chronic lymphocytic leukemia. Nat Commun 15(1):5180","DOI":"10.1038\/s41467-024-48678-3"},{"issue":"1","key":"6742_CR50","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jaci.2022.07.018","volume":"151","author":"D Smiljkovic","year":"2023","unstructured":"Smiljkovic D, Herrmann H, Sadovnik I, Gamperl S, Berger D, Stefanzl G et al (2023) Expression and regulation of siglec-6 (CD327) on human mast cells and basophils. J Allergy Clin Immunol 151(1):202\u201311","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"6742_CR51","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.3390\/cells11071138","volume":"11","author":"PA Robida","year":"2022","unstructured":"Robida PA, Rische CH, Morgenstern NBB, Janarthanam R, Cao Y, Krier-Burris RA et al (2022) Functional and phenotypic characterization of siglec-6 on human mast cells. Cells 11(7):1138","journal-title":"Cells"},{"issue":"9","key":"6742_CR52","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1158\/2326-6066.CIR-18-0102","volume":"6","author":"J Chang","year":"2018","unstructured":"Chang J, Peng H, Shaffer BC, Baskar S, Wecken IC, Cyr MG et al (2018) Siglec-6 on chronic lymphocytic leukemia cells is a target for post-allogeneic hematopoietic stem cell transplantation antibodies. Cancer Immunol Res 6(9):1008\u201313","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"6742_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004850","volume":"10","author":"MG Cyr","year":"2022","unstructured":"Cyr MG, Mhibik M, Qi J, Peng H, Chang J, Gaglione EM et al (2022) Patient-derived siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia. J Immunother Cancer 10(11):e004850","journal-title":"J Immunother Cancer"},{"key":"6742_CR54","doi-asserted-by":"crossref","unstructured":"Cao X, Dai H, Cui Q, Li Z, Shen W, Pan J et al (2022) CD7-directed CAR T-cell therapy: A potential immunotherapy strategy for relapsed\/refractory acute myeloid leukemia. Experimental Hematol Oncol 29(1):67","DOI":"10.1186\/s40164-022-00318-6"},{"issue":"12","key":"6742_CR55","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1093\/intimm\/9.12.1875","volume":"9","author":"F Bonilla","year":"1997","unstructured":"Bonilla F (1997) Targeted gene disruption of murine CD7. Int Immunol 9(12):1875\u20131883","journal-title":"Int Immunol"},{"key":"6742_CR56","doi-asserted-by":"crossref","unstructured":"Chang H, Yeung J, Brandwein J, Yi Q (2007) long. CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype. Leuk Res 31(2):157\u201362","DOI":"10.1016\/j.leukres.2006.06.001"},{"issue":"1","key":"6742_CR57","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ymthe.2018.10.001","volume":"27","author":"D Gomes-Silva","year":"2019","unstructured":"Gomes-Silva D, Atilla E, Atilla PA, Mo F, Tashiro H, Srinivasan M et al (2019) CD7 CAR T cells for the therapy of acute myeloid leukemia. Mol Therapy: J Am Soc Gene Therapy 27(1):272\u2013280","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"key":"6742_CR58","doi-asserted-by":"crossref","unstructured":"Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH et al (2017) CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 130(3):285\u2013296","DOI":"10.1182\/blood-2017-01-761320"},{"key":"6742_CR59","doi-asserted-by":"crossref","unstructured":"Lee DM, Staats HF, Sundy JS, Patel DD, Sempowski GD, Scearce RM et al (1998) Immunologic characterization of CD7-deficient mice. J Immunol 15(12):5749\u20135756","DOI":"10.4049\/jimmunol.160.12.5749"},{"key":"6742_CR60","doi-asserted-by":"publisher","first-page":"1170968","DOI":"10.3389\/fimmu.2023.1170968","volume":"14","author":"J Liu","year":"2023","unstructured":"Liu J, Zhang Y, Guo R, Zhao Y, Sun R, Guo S et al (2023) Targeted CD7 CAR T-cells for treatment of T-lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances. Front Immunol 14:1170968","journal-title":"Front Immunol"},{"issue":"1","key":"6742_CR61","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1186\/s12967-022-03797-7","volume":"20","author":"Y Lu","year":"2022","unstructured":"Lu Y, Liu Y, Wen S, Kuang N, Zhang X, Li J et al (2022) Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R\/R-AML). J Transl Med 20(1):600","journal-title":"J Transl Med"},{"issue":"3","key":"6742_CR62","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1046\/j.1365-2141.2001.03139.x","volume":"115","author":"K Ogata","year":"2001","unstructured":"Ogata K, Yokose N, Shioi Y, Ishida Y, Tomiyama J, Hamaguchi H et al (2001) Reappraisal of the clinical significance of CD7 expression in association with cytogenetics in de novo acute myeloid leukaemia. Br J Haematol 115(3):612\u20135","journal-title":"Br J Haematol"},{"issue":"2","key":"6742_CR63","doi-asserted-by":"publisher","first-page":"517","DOI":"10.4049\/jimmunol.152.2.517","volume":"152","author":"H Rabinowich","year":"1994","unstructured":"Rabinowich H, Pricop L, Herberman RB, Whiteside TL (1994) Expression and function of CD7 molecule on human natural killer cells. J Immunol 152(2):517\u2013526","journal-title":"J Immunol"},{"issue":"2","key":"6742_CR64","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1084\/jem.20152008","volume":"214","author":"C Riether","year":"2017","unstructured":"Riether C, Sch\u00fcrch CM, B\u00fchrer ED, Hinterbrandner M, Huguenin AL, Hoepner S et al (2017) CD70\/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. J Exp Med 214(2):359\u201380","journal-title":"J Exp Med"},{"issue":"7","key":"6742_CR65","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1007\/s00262-023-03422-6","volume":"72","author":"J Cheng","year":"2023","unstructured":"Cheng J, Ge T, Zhu X, Wang J, Zeng Y, Mu W et al (2023) Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia. Cancer Immunol Immunother 72(7):2331\u201346","journal-title":"Cancer Immunol Immunother"},{"key":"6742_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1093750","volume":"14","author":"G Wu","year":"2023","unstructured":"Wu G, Guo S, Luo Q, Wang X, Deng W, Ouyang G et al (2023) Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia. Front Immunol 14:1093750","journal-title":"Front Immunol"},{"issue":"9","key":"6742_CR67","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","volume":"26","author":"C Riether","year":"2020","unstructured":"Riether C, Pabst T, H\u00f6pner S, Bacher U, Hinterbrandner M, Banz Y et al (2020) Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med 26(9):1459\u201367","journal-title":"Nat Med"},{"issue":"5","key":"6742_CR68","doi-asserted-by":"publisher","first-page":"100639","DOI":"10.1016\/j.xcrm.2022.100639","volume":"3","author":"J Mirazee","year":"2022","unstructured":"Mirazee J, Shah NN (2022) CD70 CAR T cells in AML: form follows function. Cell Rep Med 3(5):100639","journal-title":"Cell Rep Med"},{"key":"6742_CR69","doi-asserted-by":"crossref","unstructured":"Sauer T, Parikh K, Sharma S, Omer B, Sedloev D, Chen Q et al (2021) CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood 138(4):318\u2013330","DOI":"10.1182\/blood.2020008221"},{"key":"6742_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111299","volume":"137","author":"Z Wu","year":"2021","unstructured":"Wu Z, Zhang H, Wu M, Peng G, He Y, Wan N et al (2021) Targeting the NKG2D\/NKG2D-L axis in acute myeloid leukemia. Biomed Pharmacother 137:111299","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"6742_CR71","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S1074-7613(02)00333-3","volume":"17","author":"AM Jamieson","year":"2002","unstructured":"Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH (2002) The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17(1):19\u201329","journal-title":"Immunity"},{"key":"6742_CR72","doi-asserted-by":"crossref","unstructured":"Lanier LL (2015) NKG2D receptor and its ligands in host defense. Cancer Immunology Research 3(6):575\u201382","DOI":"10.1158\/2326-6066.CIR-15-0098"},{"issue":"4","key":"6742_CR73","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1182\/bloodadvances.2017015230","volume":"2","author":"S Mastaglio","year":"2018","unstructured":"Mastaglio S, Wong E, Perera T, Ripley J, Blombery P, Smyth MJ et al (2018) Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy. Blood Adv 2(4):335\u2013346","journal-title":"Blood Adv"},{"issue":"7768","key":"6742_CR74","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","volume":"572","author":"AM Paczulla","year":"2019","unstructured":"Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H et al (2019) Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature 572(7768):254\u20139","journal-title":"Nature"},{"key":"6742_CR75","doi-asserted-by":"publisher","first-page":"651751","DOI":"10.3389\/fimmu.2021.651751","volume":"12","author":"A Machuldova","year":"2021","unstructured":"Machuldova A, Holubova M, Caputo VS, Cedikova M, Jindra P, Houdova L et al (2021) Role of polymorphisms of NKG2D receptor and its ligands in acute myeloid leukemia and human stem cell transplantation. Front Immunol 12:651751","journal-title":"Front Immunol"},{"key":"6742_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.580328","volume":"11","author":"L Driouk","year":"2020","unstructured":"Driouk L, Gicobi JK, Kamihara Y, Rutherford K, Dranoff G, Ritz J et al (2020) Chimeric antigen receptor T cells targeting NKG2D-ligands show robust efficacy against acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Front Immunol 11:580328","journal-title":"Front Immunol"},{"issue":"1","key":"6742_CR77","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","volume":"7","author":"SH Baumeister","year":"2019","unstructured":"Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK et al (2019) Phase i trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma. Cancer Immunol Res 7(1):100\u201312","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"6742_CR78","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12964-023-01118-z","volume":"21","author":"R Alkhayer","year":"2023","unstructured":"Alkhayer R, Ponath V, Frech M, Adhikary T, Graumann J, Neubauer A et al (2023) KLF4-mediated upregulation of the NKG2D ligand MICA in acute myeloid leukemia: A novel therapeutic target identified by enchip. Cell Commun Signal: CCS 21(1):94","journal-title":"Cell Commun Signal: CCS"},{"key":"6742_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.618710","volume":"12","author":"Z Wang","year":"2021","unstructured":"Wang Z, Chen J, Wang M, Zhang L, Yu L (2021) One stone, two birds: the roles of tim-3 in acute myeloid leukemia. Front Immunol 12:618710","journal-title":"Front Immunol"},{"issue":"4","key":"6742_CR80","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2021.12587","volume":"21","author":"AM Kamal","year":"2021","unstructured":"Kamal AM, Nabih NA, Elleboudy NS, Radwan SM (2021) Expression of immune check point gene TIM-3 in patients newly diagnosed with acute myeloid leukemia: significance and impact on outcome. Oncol Lett 21(4):325","journal-title":"Oncol Lett"},{"issue":"7","key":"6742_CR81","doi-asserted-by":"publisher","first-page":"8956","DOI":"10.1002\/cam4.5549","volume":"12","author":"Z Wu","year":"2023","unstructured":"Wu Z, Ou J, Liu N, Wang Z, Chen J, Cai Z et al (2023) Upregulation of tim-3 is associated with poor prognosis in acute myeloid leukemia. Cancer Med 12(7):8956\u20138969","journal-title":"Cancer Med"},{"key":"6742_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.879471","volume":"12","author":"J Hong","year":"2022","unstructured":"Hong J, Xia L, Huang Z, Yuan X, Liang X, Dai J et al (2022) TIM-3 expression level on AML blasts correlates with presence of core binding factor translocations rather than clinical outcomes. Front Oncol 12:879471","journal-title":"Front Oncol"},{"issue":"10","key":"6742_CR83","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1182\/bloodadvances.2022008405","volume":"7","author":"T Sakoda","year":"2023","unstructured":"Sakoda T, Kikushige Y, Miyamoto T, Irifune H, Harada T, Hatakeyama K et al (2023) TIM-3 signaling hijacks the canonical wnt\/\u03b2-catenin pathway to maintain cancer stemness in acute myeloid leukemia. Blood Adv 7(10):2053\u20132065","journal-title":"Blood Adv"},{"issue":"10","key":"6742_CR84","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood.2019002779","volume":"135","author":"X He","year":"2020","unstructured":"He X, Feng Z, Ma J, Ling S, Cao Y, Gurung B et al (2020) Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood 135(10):713\u2013723","journal-title":"Blood"},{"issue":"1","key":"6742_CR85","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12935-023-03153-9","volume":"23","author":"P Klaihmon","year":"2023","unstructured":"Klaihmon P, Luanpitpong S, Kang X, Issaragrisil S (2023) Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells. Cancer Cell Int 23(1):297","journal-title":"Cancer Cell Int"},{"issue":"1","key":"6742_CR86","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","volume":"33","author":"S Haubner","year":"2019","unstructured":"Haubner S, Perna F, K\u00f6hnke T, Schmidt C, Berman S, Augsberger C et al (2019) Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia 33(1):64\u201374","journal-title":"Leukemia"},{"key":"6742_CR87","doi-asserted-by":"crossref","unstructured":"Huang W, Zheng S, Wang Q, Zhao N, Long Z (2023) Identification and validation of a prognostic risk-scoring model based on the level of TIM-3 expression in acute myeloid leukemia. Sci Rep 20(1):15658","DOI":"10.1038\/s41598-023-42700-2"},{"issue":"12","key":"6742_CR88","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1073\/pnas.1100551108","volume":"108","author":"M Jan","year":"2011","unstructured":"Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL et al (2011) Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci USA 108(12):5009\u20135014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"6742_CR89","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/mt.2013.154","volume":"21","author":"DS Ritchie","year":"2013","unstructured":"Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K et al (2013) Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther 21(11):2122\u20139","journal-title":"Mol Ther"},{"issue":"5","key":"6742_CR90","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/gt.2010.21","volume":"17","author":"S Peinert","year":"2010","unstructured":"Peinert S, Prince HM, Guru PM, Kershaw MH, Smyth MJ, Trapani JA et al (2010) Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the lewis Y antigen. Gene Ther 17(5):678\u201386","journal-title":"Gene Ther"},{"issue":"11","key":"6742_CR91","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1038\/mt.2013.234","volume":"21","author":"MK Brenner","year":"2013","unstructured":"Brenner MK (2013) CAR T cells for acute myeloid leukemia: the LeY of the land. Mol Therapy: J Am Soc Gene Therapy 21(11):1983\u20131984","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"issue":"3","key":"6742_CR92","doi-asserted-by":"publisher","first-page":"296","DOI":"10.2174\/1389450116666150223120005","volume":"18","author":"M Goswami","year":"2017","unstructured":"Goswami M, Hourigan CS (2017) Novel antigen targets for immunotherapy of acute myeloid leukemia. Curr Drug Targets 18(3):296\u2013303","journal-title":"Curr Drug Targets"},{"key":"6742_CR93","doi-asserted-by":"crossref","unstructured":"Huang D, Yu Z, Lu H, Jiang P, Qian X, Han Y et al (2024) Adhesion GPCR ADGRE2 maintains proteostasis to promote progression in acute myeloid leukemia. Cancer Res 84(13):2090\u2013108","DOI":"10.1158\/0008-5472.CAN-23-2314"},{"issue":"2","key":"6742_CR94","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.bbrc.2019.09.113","volume":"520","author":"WY Tjong","year":"2019","unstructured":"Tjong WY, Lin HH (2019) The role of the RGD motif in CD97\/ADGRE5-and EMR2\/ADGRE2-modulated tumor angiogenesis. Biochem Biophys Res Commun 520(2):243\u2013249","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"6742_CR95","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1038\/s41598-018-22849-x","volume":"8","author":"YS Huang","year":"2018","unstructured":"Huang YS, Chiang NY, Chang GW, Lin HH (2018) Membrane-association of EMR2\/ADGRE2-NTF is regulated by site-specific N-glycosylation. Sci Rep 8(1):4532","journal-title":"Sci Rep"},{"issue":"1","key":"6742_CR96","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/s41598-020-57989-6","volume":"10","author":"N Bhudia","year":"2020","unstructured":"Bhudia N, Desai S, King N, Ancellin N, Grillot D, Barnes AA et al (2020) G protein-coupling of adhesion GPCRs ADGRE2\/EMR2 and ADGRE5\/CD97, and activation of G protein signalling by an anti-EMR2 antibody. Sci Rep 10(1):1004","journal-title":"Sci Rep"},{"issue":"1","key":"6742_CR97","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1186\/s12885-024-13108-6","volume":"24","author":"A Afzal","year":"2024","unstructured":"Afzal A, Jamshaid H, Badshah Y, Shabbir M, Trembley JH, Zafar S et al (2024) Investigating the role of non-synonymous variant D67N of ADGRE2 in chronic myeloid leukemia. BMC Cancer 24(1):1354","journal-title":"BMC Cancer"},{"key":"6742_CR98","doi-asserted-by":"crossref","unstructured":"Magnani CF, Myburgh R, Brunn S, Chambovey M, Ponzo M, Volta L et al (2023) Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells. Mol Ther Oncolytics 30:56\u201371","DOI":"10.1016\/j.omto.2023.07.003"},{"key":"6742_CR99","doi-asserted-by":"crossref","unstructured":"Raeisi M, Nikhanfar AR, Nejate B, Movassaghpour Akbari AA, Dolatkhah R, Roosta Y et al (2019) Role of CD135\/CD117 on prognosis and overall survival of acute myeloid leukemia. Asian Pac J Cancer Prev 20(9):2625\u201331","DOI":"10.31557\/APJCP.2019.20.9.2625"},{"issue":"1","key":"6742_CR100","doi-asserted-by":"publisher","first-page":"15278","DOI":"10.1038\/s41598-017-15492-5","volume":"7","author":"SK Heo","year":"2017","unstructured":"Heo SK, Noh EK, Kim JY, Jeong YK, Jo JC, Choi Y et al (2017) Targeting c-KIT (CD117) by dasatinib and Radotinib promotes acute myeloid leukemia cell death. Sci Rep 7(1):15278","journal-title":"Sci Rep"},{"issue":"10","key":"6742_CR101","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1038\/s41375-020-0818-9","volume":"34","author":"R Myburgh","year":"2020","unstructured":"Myburgh R, Kiefer JD, Russkamp NF, Magnani CF, Nu\u00f1ez N, Simonis A et al (2020) Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. Leukemia 34(10):2688\u2013703","journal-title":"Leukemia"},{"issue":"5","key":"6742_CR102","first-page":"392","volume":"83","author":"N Cascavilla","year":"1998","unstructured":"Cascavilla N, Musto P, D\u2019Arena G, Melillo L, Carella AM, Petrilli MP et al (1998) CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype. Haematologica 83(5):392\u2013397","journal-title":"Haematologica"},{"key":"6742_CR103","first-page":"381","volume":"14","author":"YM El-Meligui","year":"2021","unstructured":"El-Meligui YM, Abd Elrhman HE, Salahuddin A, Hamouda MA, Kassem AB (2021) Correlation study on HLA-DR and CD117 (c-kit) expressions: its prognosis and treatment response in acute myeloid leukemia patients. Pharmacogenomics Pers Med 14:381\u2013393","journal-title":"Pharmacogenomics Pers Med"},{"key":"6742_CR104","unstructured":"Muroi K, Amemiya Y, Miura Y (1996) Specificity of CD117 expression in the diagnosis of acute myeloid leukemia. Leukemia 10(6):1048"},{"key":"6742_CR105","doi-asserted-by":"crossref","unstructured":"Lynn RC, Feng Y, Schutsky K, Poussin M, Kalota A, Dimitrov DS et al (2016) High-affinity FR\u03b2-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. Leukemia 30(6):1355\u20131364","DOI":"10.1038\/leu.2016.35"},{"issue":"22","key":"6742_CR106","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1182\/blood-2014-11-612721","volume":"125","author":"RC Lynn","year":"2015","unstructured":"Lynn RC, Poussin M, Kalota A, Feng Y, Low PS, Dimitrov DS et al (2015) Targeting of folate receptor \u03b2 on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Blood 125(22):3466\u20133476","journal-title":"Blood"},{"issue":"2","key":"6742_CR107","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<348::AID-CNCR12>3.0.CO;2-4","volume":"85","author":"JF Ross","year":"1999","unstructured":"Ross JF, Wang H, Behm FG, Mathew P, Wu M, Booth R et al (1999) Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 85(2):348\u2013357","journal-title":"Cancer"},{"key":"6742_CR108","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/1479-5876-10-157","volume":"10","author":"LE Kandalaft","year":"2012","unstructured":"Kandalaft LE, Powell DJ, Coukos G (2012) A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J Transl Med 10:157","journal-title":"J Transl Med"},{"key":"6742_CR109","doi-asserted-by":"crossref","unstructured":"Pan XQ, Zheng X, Shi G, Wang H, Ratnam M, Lee RJ (2002) Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 100(2):594\u2013602","DOI":"10.1182\/blood.V100.2.594"},{"issue":"741","key":"6742_CR110","doi-asserted-by":"publisher","first-page":"eadj9052","DOI":"10.1126\/scitranslmed.adj9052","volume":"16","author":"J Hou","year":"2024","unstructured":"Hou J, Chen Y, Cai Z, Heo GS, Yuede CM, Wang Z et al (2024) Antibody-mediated targeting of human microglial leukocyte ig-like receptor B4 attenuates amyloid pathology in a mouse model. Sci Transl Med 16(741):eadj9052","journal-title":"Sci Transl Med"},{"key":"6742_CR111","doi-asserted-by":"crossref","unstructured":"Huang F, Luo X, Zhang M, Jin L, Sun W, Chen P et al (2025) Homoharringtonine promotes FTO degradation to suppress LILRB4-Mediated immune evasion in acute monocytic leukaemia. Cell Prolif 1e70090","DOI":"10.1111\/cpr.70090"},{"key":"6742_CR112","doi-asserted-by":"crossref","unstructured":"Ogunlusi O, Sarkar M, Carter K, Chakrabarti A, Boland DJ, Nguyen T et al (2025) LILRB4 regulates circadian disruption-induced mammary tumorigenesis via non-canonical WNT signaling pathway. Oncogene","DOI":"10.52843\/cassyni.4dwhg8"},{"key":"6742_CR113","doi-asserted-by":"publisher","first-page":"149805","DOI":"10.1016\/j.gene.2025.149805","volume":"971","author":"J Pei","year":"2025","unstructured":"Pei J, Li C, Liu Q, Miao F, Zheng Z, Sun C et al (2025) LILRB4 in tumor-associated macrophage regulates macrophage polarization and glioblastoma progression via STAT3\/IL10 axis. Gene 971:149805","journal-title":"Gene"},{"key":"6742_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118253","volume":"189","author":"C Sordo-Bahamonde","year":"2025","unstructured":"Sordo-Bahamonde C, Mart\u00ednez-P\u00e9rez A, Granda-D\u00edaz R, Pascual J, Aguilar-Garc\u00eda C, Gonz\u00e1lez-Rodr\u00edguez AP et al (2025) The immune checkpoint LILRB4 promotes immune evasion and is correlated with disease progression and secondary malignancies in chronic lymphocytic leukemia. Biomed Pharmacother 189:118253","journal-title":"Biomed Pharmacother"},{"key":"6742_CR115","doi-asserted-by":"crossref","unstructured":"Yang X, Huang R, Fang M, He Y, Xie J, Liu X et al (2025) Secretogranin 2 binds LILRB4 resulting in immunosuppression. Nat Immunol 26(9):1567\u20131580","DOI":"10.1038\/s41590-025-02233-4"},{"issue":"5","key":"6742_CR116","doi-asserted-by":"publisher","first-page":"qiaf052","DOI":"10.1093\/jleuko\/qiaf052","volume":"117","author":"Z Zhou","year":"2025","unstructured":"Zhou Z, Li Y, Wu D, Xiao Y, Zeng S, Xiao Q et al (2025) Presence of LILRB4 SNP rs1048801 modulates acute myeloid leukemia progression and inhibits CD4\u2009+\u2009T cells proliferation. J Leukoc Biol 117(5):qiaf052","journal-title":"J Leukoc Biol"},{"key":"6742_CR117","doi-asserted-by":"crossref","unstructured":"Rampal R, Figueroa ME (2016) Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia. Haematologica 101(6):672\u2013679","DOI":"10.3324\/haematol.2015.141796"},{"issue":"1","key":"6742_CR118","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s10238-025-01769-x","volume":"25","author":"T Hirahata","year":"2025","unstructured":"Hirahata T, Ul Quraish R, Ul Quraish A, Ul Quraish S, Ul Quraish R (2025) WT1 gene: a potential therapeutic target for multiple cancer treatment strategies. Clin Exp Med 25(1):336","journal-title":"Clin Exp Med"},{"key":"6742_CR119","doi-asserted-by":"crossref","unstructured":"Nagler A, Esteve J, Galimard JE, Sanz J, Poire X, Collin M et al (2025) Impact of wilms\u2019 tumor 1 gene (WT1) mutation on outcome of allogeneic hematopoietic-cell transplantation for acute myeloid leukemia: a retrospective multicenter cohort study from the ALWP\/EBMT registry. Bone Marrow Transpl","DOI":"10.1038\/s41409-025-02727-7"},{"issue":"Pt 3","key":"6742_CR120","doi-asserted-by":"publisher","first-page":"148170","DOI":"10.1016\/j.ijbiomac.2025.148170","volume":"330","author":"J Zheng","year":"2025","unstructured":"Zheng J, Huang Y, Zhong S, Lio CK, Vong SI, Wang H et al (2025) The WT1 protein molecule drives the proliferation and metastasis of anaplastic thyroid carcinoma through the EMT process. Int J Biol Macromol 330(Pt 3):148170","journal-title":"Int J Biol Macromol"},{"issue":"3","key":"6742_CR121","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/leu.2016.254","volume":"31","author":"MH Qazilbash","year":"2017","unstructured":"Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S et al (2017) PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia 31(3):697\u2013704","journal-title":"Leukemia"},{"key":"6742_CR122","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.3389\/fimmu.2018.03153","volume":"9","author":"AC Herrmann","year":"2018","unstructured":"Herrmann AC, Im JS, Pareek S, Ruiz-Vasquez W, Lu S, Sergeeva A et al (2018) A novel T-cell engaging bi-specific antibody targeting the leukemia antigen PR1\/HLA-A2. Front Immunol 9:3153","journal-title":"Front Immunol"},{"issue":"1","key":"6742_CR123","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/sj.leu.2400877","volume":"12","author":"H Miwa","year":"1998","unstructured":"Miwa H, Mizutani M, Mahmud N, Yamaguchi M, Takahashi T, Shikami M et al (1998) Biphasic expression of CD4 in acute myelocytic leukemia (AML) cells: AML of monocyte origin and hematopoietic precursor cell origin. Leukemia 12(1):44\u201351","journal-title":"Leukemia"},{"key":"6742_CR124","doi-asserted-by":"crossref","unstructured":"Yu Z, Li D, Ju X (2016) li. CD4\u2009+\u2009T cells from patients with acute myeloid leukemia inhibit the proliferation of bone marrow-derived mesenchymal stem cells by secretion of miR-10a. J Cancer Res Clin Oncol 142(4):733\u201340","DOI":"10.1007\/s00432-015-2076-1"},{"key":"6742_CR125","doi-asserted-by":"crossref","unstructured":"Zeng C, Cheng TT, Ma X, Liu Y, Hua J, Chen X et al (2022 Sept) The absence of AhR in CD4\u2009+\u2009T cells in patients with acute graft-versus-host disease May be related to insufficient CTCF expression. Clin Epigenet 2(1):109","DOI":"10.1186\/s13148-022-01330-7"},{"issue":"12","key":"6742_CR126","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.3324\/haematol.2023.283154","volume":"108","author":"A Marra","year":"2023","unstructured":"Marra A, Akarca AU, Martino G, Ramsay A, Ascani S, Perriello VM et al (2023) CD47 expression in acute myeloid leukemia varies according to genotype. Haematologica 108(12):3491\u20133495","journal-title":"Haematologica"},{"key":"6742_CR127","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.omto.2021.09.005","volume":"23","author":"M Billerhart","year":"2021","unstructured":"Billerhart M, Sch\u00f6nhofer M, Schueffl H, Polzer W, Pichler J, Decker S et al (2021) CD47-targeted cancer Immunogene therapy: secreted SIRP\u03b1-fc fusion protein eradicates tumors by macrophage and NK cell activation. Mol Ther Oncolytics 23:192\u2013204","journal-title":"Mol Ther Oncolytics"},{"key":"6742_CR128","doi-asserted-by":"crossref","unstructured":"Chen Y, Zhu X, Liu H, Wang C, Chen Y, Wang H et al (2023) The application of HER2 and CD47 CAR-macrophage in ovarian cancer. J Transl Med 21(1):654","DOI":"10.1186\/s12967-023-04479-8"},{"issue":"3","key":"6742_CR129","doi-asserted-by":"publisher","first-page":"e20200839","DOI":"10.1084\/jem.20200839","volume":"218","author":"T Deuse","year":"2021","unstructured":"Deuse T, Hu X, Agbor-Enoh S, Jang MK, Alawi M, Saygi C et al (2021) The SIRP\u03b1\u2013CD47 immune checkpoint in NK cells. J Exp Med 218(3):e20200839","journal-title":"J Exp Med"},{"key":"6742_CR130","doi-asserted-by":"publisher","first-page":"117223","DOI":"10.1016\/j.lfs.2019.117223","volume":"242","author":"B Valipour","year":"2020","unstructured":"Valipour B, Abedelahi A, Naderali E, Velaei K, Movassaghpour A, Talebi M et al (2020) Cord blood stem cell derived CD16\u2009+\u2009NK cells eradicated acute lymphoblastic leukemia cells using with anti-CD47 antibody. Life Sci 242:117223","journal-title":"Life Sci"},{"issue":"9","key":"6742_CR131","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1158\/2326-6066.CIR-18-0367","volume":"7","author":"PR Nath","year":"2019","unstructured":"Nath PR, Pal-Nath D, Mandal A, Cam MC, Schwartz AL, Roberts DD (2019) Natural killer cell recruitment and activation are regulated by CD47 expression in the tumor microenvironment. Cancer Immunol Res 7(9):1547\u201361","journal-title":"Cancer Immunol Res"},{"key":"6742_CR132","doi-asserted-by":"crossref","unstructured":"Hosen N, Park CY, Tatsumi N, Oji Y, Sugiyama H, Gramatzki M et al (2007) CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci USA 26(26):11008\u201311013","DOI":"10.1073\/pnas.0704271104"},{"key":"6742_CR133","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.molimm.2025.02.001","volume":"179","author":"S Matsuo","year":"2025","unstructured":"Matsuo S, Nabekura T, Shibuya K, Shibuya A (2025) CD96 enhances the anti-viral activity of natural killer cells by promoting Ly49H-mediated activation during mouse cytomegalovirus infection. Mol Immunol 179:65\u201370","journal-title":"Mol Immunol"},{"key":"6742_CR134","doi-asserted-by":"publisher","first-page":"112958","DOI":"10.1016\/j.intimp.2024.112958","volume":"141","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Huang T, Li X, Liu G, Xian L, Mao X et al (2024) Prognostic impact of enhanced CD96 expression on NK cells by TGF-\u03b21 in AML. Int Immunopharmacol 141:112958","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"6742_CR135","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1038\/s41375-021-01208-2","volume":"35","author":"X He","year":"2021","unstructured":"He X, Feng Z, Ma J, Zhang X, Ling S, Cao Y et al (2021) CAR T cells targeting CD13 controllably induce eradication of acute myeloid leukemia with a single domain antibody switch. Leukemia 35(11):3309\u201313","journal-title":"Leukemia"},{"issue":"6","key":"6742_CR136","first-page":"945","volume":"116","author":"E Tatsumi","year":"2001","unstructured":"Tatsumi E, Saigo K, Kawano S, Nakamura F (2001) Induction of CD13 antigen in in vitro culture and assessment of negative or positive in acute myeloid leukemia cases. Am J Clin Pathol 116(6):945\u2013948","journal-title":"Am J Clin Pathol"},{"key":"6742_CR137","doi-asserted-by":"crossref","unstructured":"Shao R, Li Z, Xin H, Jiang S, Zhu Y, Liu J et al (2023) Biomarkers as targets for CAR-T\/NK cell therapy in AML. Biomark Res 11(1):65","DOI":"10.1186\/s40364-023-00501-9"},{"issue":"2","key":"6742_CR138","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41591-021-01621-1","volume":"28","author":"J Mansilla-Soto","year":"2022","unstructured":"Mansilla-Soto J, Eyquem J, Haubner S, Hamieh M, Feucht J, Paillon N et al (2022) HLA-independent T cell receptors for targeting tumors with low antigen density. Nat Med 28(2):345\u201352","journal-title":"Nat Med"},{"issue":"8","key":"6742_CR139","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.clml.2021.03.009","volume":"21","author":"MMI Mohamed","year":"2021","unstructured":"Mohamed MMI, Aref S, Agdar MA, Mabed M, El-Sokkary AMA (2021) Leukemic stem cell (CD34+\/CD38-\/TIM3+) frequency in patients with acute myeloid leukemia: clinical implications. Clin Lymphoma Myeloma Leuk 21(8):508\u2013513","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"6742_CR140","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","volume":"41","author":"S Haubner","year":"2023","unstructured":"Haubner S, Mansilla-Soto J, Nataraj S, Kogel F, Chang Q, de Stanchina E et al (2023) Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer Cell 41(11):1871\u20131891e6","journal-title":"Cancer Cell"},{"key":"6742_CR141","doi-asserted-by":"crossref","unstructured":"Raglow Z, McKenna MK, Bonifant CL, Wang W, Pasca di Magliano M, Stadlmann J et al (2022) Targeting glycans for CAR therapy: the advent of sweet cars. Mol Ther 30(9):2881\u20132890","DOI":"10.1016\/j.ymthe.2022.07.006"},{"issue":"7","key":"6742_CR142","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.7150\/ijbs.93806","volume":"20","author":"X Ren","year":"2024","unstructured":"Ren X, Lin S, Guan F, Kang H (2024) Glycosylation targeting: a paradigm shift in cancer immunotherapy. Int J Biol Sci 20(7):2607\u20132621","journal-title":"Int J Biol Sci"},{"issue":"3","key":"6742_CR143","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/1535-7163.MCT-13-0651","volume":"13","author":"FM Tuccillo","year":"2014","unstructured":"Tuccillo FM, Palmieri C, Fiume G, de Laurentiis A, Schiavone M, Falcone C et al (2014) Cancer-associated CD43 glycoforms as target of immunotherapy. Mol Cancer Ther 13(3):752\u201362","journal-title":"Mol Cancer Ther"},{"key":"6742_CR144","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1749-6632.2011.06304.x","volume":"1253","author":"MC Clark","year":"2012","unstructured":"Clark MC, Baum LG (2012) T cells modulate glycans on CD43 and CD45 during development and activation, signal regulation, and survival. Ann N Y Acad Sci 1253:58\u201367","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"6742_CR145","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002026","volume":"9","author":"D Caracciolo","year":"2021","unstructured":"Caracciolo D, Riillo C, Ballerini A, Gaipa G, Lhermitte L, Rossi M et al (2021) Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia. J Immunother Cancer 9(2):e002026","journal-title":"J Immunother Cancer"},{"issue":"19","key":"6742_CR146","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1182\/bloodadvances.2017008342","volume":"1","author":"MA Gillissen","year":"2017","unstructured":"Gillissen MA, de Jong G, Kedde M, Yasuda E, Levie SE, Moiset G et al (2017) Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in mice. Blood Adv 1(19):1551\u20131564","journal-title":"Blood Adv"},{"key":"6742_CR147","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1572407","volume":"16","author":"Y Liu","year":"2025","unstructured":"Liu Y, Wang W, Wang C, Deng J, Hu Y, Mei H et al (2025) Recent advances of chimeric antigen receptor T-cell therapy for acute myeloid leukemia. Front Immunol 16:1572407","journal-title":"Front Immunol"},{"key":"6742_CR148","doi-asserted-by":"crossref","unstructured":"Lichtenegger FS, Krupka C, Haubner S, K\u00f6hnke T, Subklewe M (2017) Recent developments in immunotherapy of acute myeloid leukemia. J Hematol Oncol 10(1):142","DOI":"10.1186\/s13045-017-0505-0"},{"issue":"5","key":"6742_CR149","doi-asserted-by":"publisher","first-page":"e009013","DOI":"10.1136\/jitc-2024-009013","volume":"12","author":"R Freeman","year":"2024","unstructured":"Freeman R, Shahid S, Khan AG, Mathew SC, Souness S, Burns ER et al (2024) Developing a membrane-proximal CD33-targeting CAR T cell. J Immunother Cancer 12(5):e009013","journal-title":"J Immunother Cancer"},{"key":"6742_CR150","doi-asserted-by":"crossref","unstructured":"Brudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127(26):3321\u20133330","DOI":"10.1182\/blood-2016-04-703751"},{"issue":"4","key":"6742_CR151","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.3390\/ijms22041944","volume":"22","author":"R Tabata","year":"2021","unstructured":"Tabata R, Chi S, Yuda J, Minami Y (2021) Emerging immunotherapy for acute myeloid leukemia. Int J Mol Sci 22(4):1944","journal-title":"Int J Mol Sci"},{"key":"6742_CR152","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1152457","volume":"14","author":"M Shahzad","year":"2023","unstructured":"Shahzad M, Nguyen A, Hussain A, Ammad-Ud-Din M, Faisal MS, Tariq E et al (2023) Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis. Front Immunol 14:1152457","journal-title":"Front Immunol"},{"key":"6742_CR153","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1422591","volume":"15","author":"J Li","year":"2024","unstructured":"Li J, Chen H, Xu C, Hu M, Li J, Chang W (2024) Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention. Front Immunol 15:1422591","journal-title":"Front Immunol"},{"key":"6742_CR154","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhu L, Zhang H, Chen S, Xiao Y (2022) CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol 13:927153","journal-title":"Front Immunol"},{"issue":"7","key":"6742_CR155","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1182\/blood.2019004583","volume":"136","author":"C R\u00f6llig","year":"2020","unstructured":"R\u00f6llig C, Kramer M, Schliemann C, Mikesch JH, Steffen B, Kr\u00e4mer A et al (2020) Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? Blood 136(7):823\u2013830","journal-title":"Blood"},{"issue":"Supplement 1","key":"6742_CR156","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1182\/blood-2024-201791","volume":"144","author":"O Batayneh","year":"2024","unstructured":"Batayneh O, Parekh D, Vazquez Almonte M, Hamacher C, Gupta A, Sandhu M et al (2024) Does time matter from diagnosis to induction in acute myeloid leukemia? Blood 144(Supplement 1):4244\u20134244","journal-title":"Blood"},{"issue":"1","key":"6742_CR157","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2008-05-157065","volume":"113","author":"MA Sekeres","year":"2009","unstructured":"Sekeres MA, Elson P, Kalaycio ME, Advani AS, Copelan EA, Faderl S et al (2009) Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood 113(1):28\u201336","journal-title":"Blood"},{"issue":"2","key":"6742_CR158","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/bjh.18381","volume":"199","author":"A Alsouqi","year":"2022","unstructured":"Alsouqi A, Rothenberger SD, Boyiadzis M, Lontos K (2022) Time from diagnosis to treatment is associated with survival in patients with acute myeloid leukaemia: an analysis of 55 985 patients from the National Cancer Database. Br J Haematol 199(2):256\u2013259","journal-title":"Br J Haematol"},{"issue":"9","key":"6742_CR159","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/cncr.31896","volume":"125","author":"P Williams","year":"2019","unstructured":"Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE et al (2019) The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 125(9):1470\u20131481","journal-title":"Cancer"},{"issue":"5","key":"6742_CR160","doi-asserted-by":"publisher","first-page":"463","DOI":"10.21147\/j.issn.1000-9604.2017.05.11","volume":"29","author":"J Tan","year":"2017","unstructured":"Tan J, Chen S, Lu Y, Yao D, Xu L, Zhang Y et al (2017) Higher PD-1 expression concurrent with exhausted CD8\u2009+\u2009T cells in patients with de novo acute myeloid leukemia. Chin J Cancer Res 29(5):463\u201370","journal-title":"Chin J Cancer Res"},{"issue":"6","key":"6742_CR161","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1007\/s00277-025-06418-7","volume":"104","author":"K Sun","year":"2025","unstructured":"Sun K, Shi ZY, Wang YZ, Xie DH, Liu YR, Jiang Q et al (2025) The expression patterns and prognostic significance of PD-1 and TIM-3 on T cells and the differentiated subsets in acute myeloid leukemia. Ann Hematol 104(6):3235\u201350","journal-title":"Ann Hematol"},{"key":"6742_CR162","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-0185-8","volume":"8","author":"J Tan","year":"2020","unstructured":"Tan J, Yu Z, Huang J, Chen Y, Huang S, Yao D et al (2020) Increased PD-1\u2009+\u2009tim-3\u2009+\u2009exhausted T cells in bone marrow may influence the clinical outcome of patients with AML. Biomark Res 8:6","journal-title":"Biomark Res"},{"issue":"1","key":"6742_CR163","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1038\/s41467-023-41994-0","volume":"14","author":"H Mumme","year":"2023","unstructured":"Mumme H, Thomas BE, Bhasin SS, Krishnan U, Dwivedi B, Perumalla P et al (2023) Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia. Nat Commun 14(1):6209","journal-title":"Nat Commun"},{"key":"6742_CR164","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1376554","volume":"12","author":"B Guijarro-Albaladejo","year":"2024","unstructured":"Guijarro-Albaladejo B, Marrero-Cepeda C, Rodr\u00edguez-Arbol\u00ed E, Sierro-Mart\u00ednez B, P\u00e9rez-Sim\u00f3n JA, Garc\u00eda-Guerrero E (2024) Chimeric antigen receptor (CAR) modified T cells in acute myeloid leukemia: limitations and expectations. Front Cell Dev Biol 12:1376554","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"6742_CR165","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1158\/1078-0432.CCR-08-3010","volume":"15","author":"MJ Szczepanski","year":"2009","unstructured":"Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A et al (2009) Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res: Off J Am Assoc Cancer Res 15(10):3325\u20133332","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"18","key":"6742_CR166","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1182\/blood-2009-02-206946","volume":"114","author":"R Le Dieu","year":"2009","unstructured":"Le Dieu R, Taussig DC, Ramsay AG, Mitter R, Miraki-Moud F, Fatah R et al (2009) Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood 114(18):3909\u20133916","journal-title":"Blood"},{"key":"6742_CR167","doi-asserted-by":"crossref","unstructured":"Bommhardt U, Schraven B, Simeoni L (2019) Beyond TCR signaling: emerging functions of Lck in cancer and immunotherapy. Int J Mol Sci 20(14):3500","DOI":"10.3390\/ijms20143500"},{"issue":"9","key":"6742_CR168","first-page":"1163","volume":"12","author":"LM Fern\u00e1ndez-Aguilar","year":"2023","unstructured":"Fern\u00e1ndez-Aguilar LM, Vico-Barranco I, Arbulo-Echevarria MM, Aguado E (2023) A story of kinases and adaptors: the role of lck, ZAP-70 and LAT in switch panel governing T-cell development and activation. Biology (Basel) 12(9):1163","journal-title":"Biology (Basel)"},{"issue":"5","key":"6742_CR169","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a002279","volume":"2","author":"H Wang","year":"2010","unstructured":"Wang H, Kadlecek TA, Au-Yeung BB, Goodfellow HES, Hsu LY, Freedman TS et al (2010) ZAP-70: an essential kinase in T-cell signaling. Cold Spring Harb Perspect Biol 2(5):a002279","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"6742_CR170","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01166","volume":"9","author":"D Mougiakakos","year":"2019","unstructured":"Mougiakakos D (2019) The induction of a permissive environment to promote T cell immune evasion in acute myeloid leukemia: the metabolic perspective. Front Oncol 9:1166","journal-title":"Front Oncol"},{"key":"6742_CR171","doi-asserted-by":"crossref","unstructured":"Kreitz J, Sch\u00f6nfeld C, Seibert M, Stolp V, Alshamleh I, Oellerich T et al (2019) Metabolic plasticity of acute myeloid leukemia. Cells 8(8):805","DOI":"10.3390\/cells8080805"},{"issue":"567","key":"6742_CR172","doi-asserted-by":"publisher","first-page":"eabb8969","DOI":"10.1126\/scitranslmed.abb8969","volume":"12","author":"FM Uhl","year":"2020","unstructured":"Uhl FM, Chen S, O\u2019Sullivan D, Edwards-Hicks J, Richter G, Haring E et al (2020) Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans. Sci Transl Med 12(567):eabb8969","journal-title":"Sci Transl Med"},{"issue":"19","key":"6742_CR173","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1182\/bloodadvances.2020001797","volume":"4","author":"RK Das","year":"2020","unstructured":"Das RK, O\u2019Connor RS, Grupp SA, Barrett DM (2020) Lingering effects of chemotherapy on mature T cells impair proliferation. Blood Adv 4(19):4653\u20134664","journal-title":"Blood Adv"},{"issue":"4","key":"6742_CR174","doi-asserted-by":"publisher","first-page":"e010709","DOI":"10.1136\/jitc-2024-010709","volume":"13","author":"C Junkuhn","year":"2025","unstructured":"Junkuhn C, Schiele P, Walter AL, Hamm F, Obermayer B, Busch D et al (2025) Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-hodgkin\u2019s lymphoma. J ImmunoTher Cancer 13(4):e010709","journal-title":"J ImmunoTher Cancer"},{"key":"6742_CR175","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303935","volume":"14","author":"B Lickefett","year":"2023","unstructured":"Lickefett B, Chu L, Ortiz-Maldonado V, Warmuth L, Barba P, Doglio M et al (2023) Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front Immunol 14:1303935","journal-title":"Front Immunol"},{"key":"6742_CR176","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2147\/JBM.S312140","volume":"12","author":"I Rinaldi","year":"2021","unstructured":"Rinaldi I, Sari RM, Tedhy VU, Winston K (2021) Leukapheresis does not improve early survival outcome of acute myeloid leukemia with leukostasis patients - a dual-center retrospective cohort study. J Blood Med 12:623\u2013633","journal-title":"J Blood Med"},{"key":"6742_CR177","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.omtm.2021.10.006","volume":"23","author":"B Deng","year":"2021","unstructured":"Deng B, Pan J, Liu Z, Liu S, Chen Y, Qu X et al (2021) Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL. Mol ther. Methods Clin Dev 23:633\u2013643","journal-title":"Methods Clin Dev"},{"issue":"6","key":"6742_CR178","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3390\/biomedicines12061194","volume":"12","author":"D Damiani","year":"2024","unstructured":"Damiani D, Tiribelli M (2024) CAR-T cells in acute myeloid leukemia: where do we stand? Biomedicines 12(6):1194","journal-title":"Biomedicines"},{"key":"6742_CR179","doi-asserted-by":"crossref","unstructured":"Naik S, Velasquez MP, Gottschalk S (2024) Chimeric antigen receptor T-cell therapy in childhood acute myeloid leukemia: How far are we from a clinical application? Haematologica 109(6):1656\u201367","DOI":"10.3324\/haematol.2023.283817"},{"issue":"1","key":"6742_CR180","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-025-01708-z","volume":"18","author":"J Yin","year":"2025","unstructured":"Yin J, Cui QY, Dai HP, Qu CJ, Li Z, Kang LQ et al (2025) CD19 CAR-T in relapsed t(8;21) AML: A single-center prospective phase II clinical trial. J Hematol Oncol 18(1):53","journal-title":"J Hematol Oncol"},{"key":"6742_CR181","unstructured":"Wang H, Feng S, Zhu Y, Zhang Y, Zhou Z, Nian Z et al (2024) The tandem CD33-CLL1 CAR-T as an approach to treat acute myeloid leukemia. Blood Transfus = Trasfusione Del Sangue"},{"issue":"5","key":"6742_CR182","doi-asserted-by":"publisher","first-page":"114145","DOI":"10.1016\/j.celrep.2024.114145","volume":"43","author":"NW Frankel","year":"2024","unstructured":"Frankel NW, Deng H, Yucel G, Gainer M, Leemans N, Lam A et al (2024) Precision off-the-shelf natural killer cell therapies for oncology with logic-gated gene circuits. Cell Rep 43(5):114145","journal-title":"Cell Rep"},{"key":"6742_CR183","doi-asserted-by":"publisher","first-page":"100751","DOI":"10.1016\/j.omto.2023.100751","volume":"31","author":"JC Boucher","year":"2023","unstructured":"Boucher JC, Shrestha B, Vishwasrao P, Leick M, Cervantes EV, Ghafoor T et al (2023) Bispecific CD33\/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Mol Ther Oncolytics 31:100751","journal-title":"Mol Ther Oncolytics"},{"issue":"7952","key":"6742_CR184","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","volume":"615","author":"AM Tousley","year":"2023","unstructured":"Tousley AM, Rotiroti MC, Labanieh L, Rysavy LW, Kim WJ, Lareau C et al (2023) Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature 615(7952):507\u201316","journal-title":"Nature"},{"issue":"623","key":"6742_CR185","doi-asserted-by":"publisher","first-page":"eabh1962","DOI":"10.1126\/scitranslmed.abh1962","volume":"13","author":"A Katsarou","year":"2021","unstructured":"Katsarou A, Sj\u00f6strand M, Naik J, Mansilla-Soto J, Kefala D, Kladis G et al (2021) Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. Sci Transl Med 13(623):eabh1962","journal-title":"Sci Transl Med"},{"issue":"3","key":"6742_CR186","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.ymthe.2021.11.013","volume":"30","author":"F Fei","year":"2022","unstructured":"Fei F, Rong L, Jiang N, Wayne AS, Xie J (2022) Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor. Mol Ther: J Am Soc Gene Ther 30(3):1215\u20131226","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"issue":"591","key":"6742_CR187","doi-asserted-by":"publisher","first-page":"eabe7378","DOI":"10.1126\/scitranslmed.abe7378","volume":"13","author":"JH Choe","year":"2021","unstructured":"Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA et al (2021) SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med 13(591):eabe7378","journal-title":"Sci Transl Med"},{"issue":"2","key":"6742_CR188","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/biom11020238","volume":"11","author":"C Bao","year":"2021","unstructured":"Bao C, Gao Q, Li LL, Han L, Zhang B, Ding Y et al (2021) The application of nanobody in CAR-T therapy. Biomolecules 11(2):238","journal-title":"Biomolecules"},{"issue":"1","key":"6742_CR189","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-022-00371-7","volume":"10","author":"P Safarzadeh Kozani","year":"2022","unstructured":"Safarzadeh Kozani P, Naseri A, Mirarefin SMJ, Salem F, Nikbakht M, Evazi Bakhshi S et al (2022) Nanobody-based CAR-T cells for cancer immunotherapy. Biomark Res 10(1):24","journal-title":"Biomark Res"},{"issue":"10","key":"6742_CR190","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood.2024024861","volume":"145","author":"P Lu","year":"2025","unstructured":"Lu P, Zhang X, Yang J, Li J, Qiu L, Gong M et al (2025) Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia. Blood 145(10):1022\u20131033","journal-title":"Blood"},{"issue":"1","key":"6742_CR191","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2458843","volume":"14","author":"X Zhang","year":"2025","unstructured":"Zhang X, Feng Z, Pranatharthi Haran A, Hua X (2025) Dual nanobody-redirected and bi-specific CD13\/TIM3 CAR T cells eliminate AML xenografts without toxicity to human HSCs. Oncoimmunology 14(1):2458843","journal-title":"Oncoimmunology"},{"key":"6742_CR192","doi-asserted-by":"crossref","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F (2024) Humanization of the antigen-recognition domain does not impinge on the antigen-binding, cytokine secretion, and antitumor reactivity of humanized nanobody-based CD19-redirected CAR-T cells. J Transl Med 25(1):679","DOI":"10.1186\/s12967-024-05461-8"},{"issue":"1","key":"6742_CR193","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/s12935-021-02151-z","volume":"21","author":"H Wang","year":"2021","unstructured":"Wang H, Wang L, Li Y, Li G, Zhang X, Jiang D et al (2021) Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells. Cancer Cell Int 21(1):450","journal-title":"Cancer Cell Int"},{"key":"6742_CR194","doi-asserted-by":"crossref","unstructured":"Xia B, Lin K, Wang X, Chen F, Zhou M, Li Y et al (2023) Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment. Mol Ther Oncolytics 30:86\u2013102","DOI":"10.1016\/j.omto.2023.07.007"},{"issue":"11","key":"6742_CR195","doi-asserted-by":"publisher","first-page":"e009110","DOI":"10.1136\/jitc-2024-009110","volume":"12","author":"F Meeus","year":"2024","unstructured":"Meeus F, Funeh CN, Awad RM, Zeven K, Autaers D, De Becker A et al (2024) Preclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity. J ImmunoTher Cancer 12(11):e009110","journal-title":"J ImmunoTher Cancer"},{"key":"6742_CR196","doi-asserted-by":"crossref","unstructured":"Haubner S, Subklewe M, Sadelain M (2024) Honing CAR T cells to tackle acute myeloid leukemia. Blood J blood.2024024063","DOI":"10.1182\/blood.2024024063"},{"issue":"1","key":"6742_CR197","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.2003532","volume":"10","author":"CM Seitz","year":"2021","unstructured":"Seitz CM, Mittelstaet J, Atar D, Hau J, Reiter S, Illi C et al (2021) Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting. Oncoimmunology 10(1):2003532","journal-title":"Oncoimmunology"},{"issue":"10","key":"6742_CR198","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41375-024-02351-2","volume":"38","author":"D Atar","year":"2024","unstructured":"Atar D, Ruoff L, Mast AS, Krost S, Moustafa-Oglou M, Scheuermann S et al (2024) Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia. Leukemia 38(10):2183\u201395","journal-title":"Leukemia"},{"issue":"12","key":"6742_CR199","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1038\/s41375-024-02409-1","volume":"38","author":"L Volta","year":"2024","unstructured":"Volta L, Myburgh R, Pellegrino C, Koch C, Maurer M, Manfredi F et al (2024) Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells. Leukemia 38(12):2598\u20132613","journal-title":"Leukemia"},{"issue":"10","key":"6742_CR200","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1158\/1535-7163.MCT-20-1030","volume":"20","author":"PD Rennert","year":"2021","unstructured":"Rennert PD, Dufort FJ, Su L, Sanford T, Birt A, Wu L et al (2021) Anti-CD19 CAR T cells that secrete a biparatopic anti-CLEC12A bridging protein have potent activity against highly aggressive acute myeloid leukemia in vitro and in vivo. Mol Cancer Ther 20(10):2071\u20132081","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"6742_CR201","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/s41375-023-01905-0","volume":"37","author":"D Nixdorf","year":"2023","unstructured":"Nixdorf D, Sponheimer M, Berghammer D, Engert F, Bader U, Philipp N et al (2023) Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML. Leukemia 37(6):1298\u2013310","journal-title":"Leukemia"},{"key":"6742_CR202","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.3389\/fimmu.2020.01787","volume":"11","author":"L You","year":"2020","unstructured":"You L, Han Q, Zhu L, Zhu Y, Bao C, Yang C et al (2020) Decitabine-mediated epigenetic reprograming enhances anti-leukemia efficacy of CD123-targeted chimeric antigen receptor T-cells. Front Immunol 11:1787","journal-title":"Front Immunol"},{"issue":"5","key":"6742_CR203","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","volume":"40","author":"MB Leick","year":"2022","unstructured":"Leick MB, Silva H, Scarf\u00f2 I, Larson R, Choi BD, Bouffard AA et al (2022) Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell 40(5):494\u2013508e5","journal-title":"Cancer Cell"},{"issue":"5","key":"6742_CR204","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s00428-024-03741-8","volume":"485","author":"ML Marques-Piubelli","year":"2024","unstructured":"Marques-Piubelli ML, Kumar B, Basar R, Panowski S, Srinivasan S, Norwood K et al (2024) Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents. Virchows Arch 485(5):937\u201341","journal-title":"Virchows Arch"},{"issue":"1","key":"6742_CR205","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1038\/s41467-021-26683-0","volume":"12","author":"N El Khawanky","year":"2021","unstructured":"El Khawanky N, Hughes A, Yu W, Myburgh R, Matschulla T, Taromi S et al (2021) Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat Commun 12(1):6436","journal-title":"Nat Commun"},{"issue":"4","key":"6742_CR206","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/leu.2008.354","volume":"23","author":"A Poggi","year":"2009","unstructured":"Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR (2009) Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 23(4):641\u2013648","journal-title":"Leukemia"},{"issue":"12","key":"6742_CR207","doi-asserted-by":"publisher","first-page":"e20231235","DOI":"10.1084\/jem.20231235","volume":"220","author":"R Marone","year":"2023","unstructured":"Marone R, Landmann E, Devaux A, Lepore R, Seyres D, Zuin J et al (2023) Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy. J Exp Med 220(12):e20231235","journal-title":"J Exp Med"},{"key":"6742_CR208","doi-asserted-by":"crossref","unstructured":"Wellhausen N, O\u2019Connell RP, Lesch S, Engel NW, Rennels AK, Gonzales D et al (2023) Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy. Sci Transl Med 20(714):eadi1145","DOI":"10.1126\/scitranslmed.adi1145"},{"key":"6742_CR209","doi-asserted-by":"crossref","unstructured":"Garaud\u00e9 S, Marone R, Lepore R, Devaux A, Beerlage A, Seyres D et al (2024) Selective haematological cancer eradication with preserved haematopoiesis. Nature 630(8017):728\u2013735","DOI":"10.1038\/s41586-024-07456-3"},{"key":"6742_CR210","doi-asserted-by":"crossref","unstructured":"Casirati G, Cosentino A, Mucci A, Salah Mahmoud M, Ugarte Zabala I, Zeng J et al (2023) Epitope editing enables targeted immunotherapy of acute myeloid leukaemia. Nature 621(7978):404\u2013414","DOI":"10.1038\/s41586-023-06496-5"},{"issue":"6","key":"6742_CR211","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"MY Kim","year":"2018","unstructured":"Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH et al (2018) Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell 173(6):1439\u20131453e19","journal-title":"Cell"},{"issue":"3","key":"6742_CR212","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s11864-023-01049-4","volume":"24","author":"X Cao","year":"2023","unstructured":"Cao X, Jin X, Zhang X, Utsav P, Zhang Y, Guo R et al (2023) Small-Molecule compounds boost CAR-T cell therapy in hematological malignancies. Curr Treat Options Oncol 24(3):184\u2013211","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"6742_CR213","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2021.11847","volume":"23","author":"G Lin","year":"2021","unstructured":"Lin G, Zhang Y, Yu L, Wu D (2021) Cytotoxic effect of CLL\u20111 CAR\u2011T cell immunotherapy with PD\u20111 silencing on relapsed\/refractory acute myeloid leukemia. Mol Med Rep 23(3):208","journal-title":"Mol Med Rep"},{"key":"6742_CR214","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1145441","volume":"14","author":"L Tang","year":"2023","unstructured":"Tang L, Kong Y, Wang H, Zou P, Sun T, Liu Y et al (2023) Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia. Front Immunol 14:1145441","journal-title":"Front Immunol"},{"issue":"10","key":"6742_CR215","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1016\/j.ymthe.2022.06.006","volume":"30","author":"J Tipanee","year":"2022","unstructured":"Tipanee J, Samara-Kuko E, Gevaert T, Chuah MK, VandenDriessche T (2022) Universal allogeneic CAR t cells engineered with sleeping beauty transposons and CRISPR-CAS9 for cancer immunotherapy. Mol Ther: J Am Soc Gene Ther 30(10):3155\u20133175","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"issue":"2","key":"6742_CR216","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.ymthe.2020.10.019","volume":"29","author":"X Wang","year":"2021","unstructured":"Wang X, Cabrera FG, Sharp KL, Spencer DM, Foster AE, Bayle JH (2021) Engineering tolerance toward allogeneic CAR-T cells by regulation of MHC surface expression with human herpes virus-8 proteins. Mol Ther 29(2):718\u2013733","journal-title":"Mol Ther"},{"issue":"4","key":"6742_CR217","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/2326-6066.CIR-23-0679","volume":"12","author":"\u00c9 Degagn\u00e9","year":"2024","unstructured":"Degagn\u00e9 \u00c9, Donohoue PD, Roy S, Scherer J, Fowler TW, Davis RT et al (2024) High-Specificity CRISPR-Mediated genome engineering in Anti-BCMA allogeneic CAR T cells suppresses allograft rejection in preclinical models. Cancer Immunol Res 12(4):462\u2013477","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"6742_CR218","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1016\/j.ymthe.2024.06.033","volume":"32","author":"I Porreca","year":"2024","unstructured":"Porreca I, Blassberg R, Harbottle J, Joubert B, Mielczarek O, Stombaugh J et al (2024) An aptamer-mediated base editing platform for simultaneous knockin and multiple gene knockout for allogeneic CAR-T cells generation. Mol Ther: J Am Soc Gene Ther 32(8):2692\u20132710","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"issue":"10","key":"6742_CR219","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.ymthe.2020.06.022","volume":"28","author":"C Sommer","year":"2020","unstructured":"Sommer C, Cheng HY, Nguyen D, Dettling D, Yeung YA, Sutton J et al (2020) Allogeneic FLT3 CAR T cells with an off-switch exhibit potent activity against AML and can be depleted to expedite bone marrow recovery. Mol Therapy: J Am Soc Gene Therapy 28(10):2237\u20132251","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"issue":"1","key":"6742_CR220","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1182\/hematology.2023000455","volume":"2023","author":"M Subklewe","year":"2023","unstructured":"Subklewe M, B\u00fccklein V, Sallman D, Daver N (2023) Novel immunotherapies in the treatment of AML: is there hope? Hematology 2023(1):691\u2013701","journal-title":"Hematology"},{"issue":"Supplement 1","key":"6742_CR221","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1182\/blood-2024-207659","volume":"144","author":"Y Lin","year":"2024","unstructured":"Lin Y, Zhao D, Deng B, Liu D, Yan H, Li B et al (2024) The safety and efficacy of CD33 CAR-T therapy for RR AML after HSCT. Blood 144(Supplement 1):3467\u20133467","journal-title":"Blood"},{"issue":"10","key":"6742_CR222","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood.2024027442","volume":"145","author":"M Mamonkin","year":"2025","unstructured":"Mamonkin M (2025) CD7 CAR-T: a bridge to transplant in AML. Blood 145(10):995\u2013996","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06742-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06742-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06742-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:02:56Z","timestamp":1770267776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06742-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":222,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["6742"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06742-6","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal welfare statement"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}